*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available in the Division of Plasma Protein Therapeutics (DPPT), within the Office of Tissues and Advanced Therapies (OTAT), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
For this research project, the participant will join a research program that broadly studies the immune responses to therapeutic proteins (immunogenicity). They will collaborate with experimental biologists and immunologists as well as clinicians to identify genetic risk factors for immunogenicity. The following articles in the literature provide examples of the range of work performed in our group:
- Front. Immunol. 10: 2894, 2019
- Blood Adv. 3: 2668-2678, 2019
- AAPS J. 21: 96, 2019
- Blood Adv. 3: 1429-1440, 2019
- Mol Ther Methods Clin Dev. 10: 105-112, 2018
- Sci. Transl. Med. 9: eaag1286, 2017
- Blood 125: 223-228, 2015
- Nature Med. 19: 1318-1324, 2013
- PLoS Comput. Biol., 9, e1003066, 2013
- Nature Biotechnol. 29: 870-873, 2011
The participant will conduct scientific research which is important for ensuring the safety of therapeutic proteins. There are opportunities to learn new technologies and authorship in peer reviewed articles. The training using advanced methodologies will prepare the participant for careers in the academic, government and the pharmaceutical industries. The training is also well suited for students considering applying to graduate or medical school.
Anticipated Appointment Start Date: September 1, 2021; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity in your email.